Phaseline

Targets › VWF

VWF (von Willebrand factor): drug programs, companies and trials

6 programs from 6 companies in 7 trials: 3 Phase 3, 2 Phase 4, 1 Phase 1, 1 Phase 2; Hematology, Other; next expected readout Dec 2026.

Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. (UniProt, P04275)

Open in Phaseline: the race on VWF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, Basel, SwitzerlandWilate
1:1 balanced mixture of von Willebrand Factor and Coagulation Factor VIII
F8, VWFPhase 4BleedingNov 2027
Grifols BiologicalsAlphanate SD/HT
Factor VIII/von Willebrand Factor (vWF) concentrate
F8, VWFPhase 4Von Willebrand Disease–
TakedaVonicog Alfa
von Willebrand factor exogenous protein
VWFPhase 3Von Willebrand Disease (VWD)Nov 2027
Unity Health TorontoWilate
Von Willebrand Factor and Factor VIII concentrate
VWF, F8Phase 3Von Willebrand DiseasesDec 2027
Medical University of ViennaBT200
Aptamer directed against the A1 domain of von Willebrand factor
VWFPhase 2Von Willebrand Disease (VWD), Type 2–
University of VirginiaVon Willebrand Factor Human
von Willebrand factor exogenous protein
VWFPhase 1Bleeding DisorderDec 2026

Conditions

Von Willebrand Disease (VWD) (2) Von Willebrand Diseases (1) Bleeding Disorder (1) Bleeding (1) Von Willebrand Disease (VWD), Type 2 (1) Von Willebrand Disease (1)

Modalities

protein or peptide (3), small molecule (3)

Companies

Takeda (1) Unity Health Toronto (1) University of Virginia (1) University Hospital, Basel, Switzerland (1) Medical University of Vienna (1) Grifols Biologicals (1)

Related targets

F8 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.